logo-loader

Full interview: Polarean Imaging begins enrolment for phase III clinical trial at third US site

Published: 10:27 06 Aug 2019 EDT

Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site.

The company’s drug-device combination uses hyperpolarised 129-Xenon gas to make magnetic resonance imaging (MRI) more effective in assessing lung function.

Polarean Imaging receives "clear indication of belief in the company" from...

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) CEO Christopher von Jako speaks to Thomas Warner from Proactive after the medical imaging technology company announced that NUKEM Isotopes GmbH recently increased its stake in Polarean to over 10%, marking a shift in the company's shareholder...

on 01/17/2024